Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

Dupixent demonstrated superior efficacy in ... 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the EVEREST Phase 4 trial ...

French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

About Dupixent Dupixent, which was invented using Regeneron’s proprietary VelocImmune ® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4 ...

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...

Paris: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent ...